Short answer
MYRIAD GENETICS INC (MYGN) filed an 8-K current report with the SEC on October 20, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Myriad selling prenatal health business to Labcorp for $210 million cash plus inventory value at closing.
MYRIAD GENETICS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Myriad selling prenatal health business to Labcorp for $210 million cash plus inventory value at closing
- Divestiture includes Foresight, Prequel, FirstGene and SneakPeek tests, reshaping Myriad’s portfolio
- Closing requires antitrust, state healthcare approvals, third-party consents and other customary conditions
- Buyer termination fee up to $10.5 million if specified regulatory clearances fail
- Expected outside closing date February 19, 2027, extendable to October 19, 2027 for regulatory delays
Item 7.01 · Regulation FD Disclosure
- Press release announces Myriad Genetics’ entry into a Purchase Agreement
- Purchase Agreement may signal an acquisition, divestiture, or strategic transaction requiring review of Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Myriad selling Prenatal Health business to Labcorp for $210 million cash plus closing inventory value
- Portfolio includes Prequel, Foresight, SneakPeek and FirstGene tests, serving over 600,000 patients
- Proceeds expected to strengthen Myriad’s balance sheet and support cancer-care strategic investments
- Transaction subject to regulatory clearance, with closing expected by early 2027
- Labcorp projects approximately $160 million first-year revenue contribution and slight adjusted earnings accretion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other MYRIAD GENETICS INC 8-K filings
Get the next MYGN 8-K as it lands
Follow MYGN for push alerts, or ask the research agent what this filing means.